Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Biomea Fusion, Inc. Common Stock (BMEA)

Pharmaceutical Preparations

https://www.biomeafusion.com

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

900 MIDDLEFIELD ROAD, 4TH FLOOR
REDWOOD CITY, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/16/2021

Market Cap

207,484,446

Shares Outstanding

35,710,000

Weighted SO

35,705,786

Total Employees

N/A

Upcoming Earnings

07/29/2024

Similar Tickers

EWTX --.--%

HOWL --.--%

CGEM --.--%

DSGN --.--%

IKNA --.--%

Beta

-0.5380

Last Div

0.0000

Range

3.61-22.74

Chg

-0.0900

Avg Vol

1359343

Mkt Cap

207484446

Exch

NASDAQ

Country

US

Phone

650 980 9099

DCF Diff

0.8662

DCF

4.8838

Div Yield

0.0000

P/S

33.7813

EV Multiple

-0.7138

P/FV

1.9869

Div Yield %

0.0000

P/E

-1.4789

PEG

0.0569

Payout

0.0000

Current Ratio

4.6214

Quick Ratio

4.6214

Cash Ratio

4.5021

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

695.1699

CCC

-695.1699

Gross Margin

0.5018

Op Margin

-24.1622

Pretax Margin

-22.7369

Net Margin

-22.7369

Eff Tax Rate

-0.0125

ROA

-1.0256

ROE

-0.9186

ROCE

-1.3370

NI/EBT

1.0000

EBT/EBIT

0.9410

EBIT/Rev

-24.1622

Debt Ratio

0.0760

D/E

0.0995

LT Debt/Cap

0.0635

Total Debt/Cap

0.0905

Int Coverage

-151.4327

CF/Debt

-10.7725

Equity Multi

1.3099

Rec Turnover

0.0000

Pay Turnover

0.5251

Inv Turnover

0.0000

FA Turnover

0.4813

Asset Turnover

0.0451

OCF/Share

-3.0910

FCF/Share

-3.0949

Cash/Share

3.1430

OCF/Sales

-18.1389

FCF/OCF

1.0013

CF Coverage

-10.7725

ST Coverage

-33.8732

CapEx Coverage

-790.1348

Div&CapEx Cov

-790.1348

P/BV

1.9869

P/B

1.9869

P/S

33.7813

P/E

-1.4789

P/FCF

-1.8600

P/OCF

-1.8538

P/CF

-1.8538

PEG

0.0569

P/S

33.7813

EV Multiple

-0.7138

P/FV

1.9869

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 18, 03:15 Biomea Fusion Announces Pricing of Public Offering of Securities GlobeNewswire Inc. Mar 25, 23:00 Biomea Fusion Announces Leadership Transition GlobeNewswire Inc. Dec 16, 23:15 Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) GlobeNewswire Inc. Jan 09, 11:02 Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Dec 11, 09:25 Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH GlobeNewswire Inc. Dec 09, 17:30 Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts GlobeNewswire Inc. Dec 09, 17:30 Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts GlobeNewswire Inc. Dec 09, 17:30 Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts GlobeNewswire Inc. Dec 09, 17:30 Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts GlobeNewswire Inc. Dec 09, 17:30 Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts GlobeNewswire Inc. Dec 09, 17:30 Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts GlobeNewswire Inc. Dec 09, 17:30 Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts GlobeNewswire Inc. Dec 09, 17:30 Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts GlobeNewswire Inc. Dec 09, 17:30 Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts GlobeNewswire Inc. Dec 09, 17:30 Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts GlobeNewswire Inc. Dec 09, 17:30 Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts GlobeNewswire Inc. Dec 09, 17:30 Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts GlobeNewswire Inc. Dec 07, 09:15 Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Dis GlobeNewswire Inc. Dec 05, 08:30 Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes GlobeNewswire Inc. Nov 27, 08:30 Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024

Revenue Product Segmentation